Lv1
40 积分 2026-09-22 加入
Trial in progress: Phase 1 study of the selective protein degrader ASP4396 in patients with locally advanced or metastatic solid tumors with KRAS G12D mutations
5小时前
求助中
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
6小时前
已完结
皖公网安备34019202002308
